Trials / Completed
CompletedNCT05620836
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 619 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Povorcitinib | Oral, Tablet |
| DRUG | Placebo | Oral, Tablet |
Timeline
- Start date
- 2023-02-22
- Primary completion
- 2025-01-07
- Completion
- 2025-11-21
- First posted
- 2022-11-17
- Last updated
- 2026-01-09
Locations
101 sites across 11 countries: United States, Australia, Bulgaria, Canada, Denmark, France, Germany, Italy, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05620836. Inclusion in this directory is not an endorsement.